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AbstrACt
Introduction Left ventricular ejection fraction (LVEF) 
≤35%, as current significant implantable cardioverter-
defibrillator (ICD) indication for primary prevention of 
sudden cardiac death (SCD) in heart failure (HF) patients, 
has been widely recognised to be inefficient. Improvement 
of patient selection for low LVEF (≤35%) is needed to 
optimise deployment of ICD. Most of the existing prediction 
models are not appropriate to identify ICD candidates at 
high risk of SCD in HF patients with low LVEF. Compared 
with traditional statistical analysis, machine learning (ML) 
can employ computer algorithms to identify patterns in 
large datasets, analyse rules automatically and build both 
linear and non-linear models in order to make data-driven 
predictions. This study is aimed to develop and validate 
new models using ML to improve the prediction of SCD in 
HF patients with low LVEF.
Methods and analysis We will conduct a 
retroprospective, multicentre, observational registry 
of Chinese HF patients with low LVEF. The HF patients 
with LVEF ≤35% after optimised medication at least 
3 months will be enrolled in this study. The primary 
endpoints are all-cause death and SCD. The secondary 
endpoints are malignant arrhythmia, sudden cardiac 
arrest, cardiopulmonary resuscitation and rehospitalisation 
due to HF. The baseline demographic, clinical, biological, 
electrophysiological, social and psychological variables 
will be collected. Both ML and traditional multivariable Cox 
proportional hazards regression models will be developed 
and compared in the prediction of SCD. Moreover, the ML 
model will be validated in a prospective study.
Ethics and dissemination The study protocol has been 
approved by the Ethics Committee of the First Affiliated 
Hospital of Nanjing Medical University (2017-SR-06). All 
results of this study will be published in international peer-
reviewed journals and presented at relevant conferences.
trial registration number ChiCTR-POC-17011842; Pre-
results.
IntroduCtIon
Heart failure (HF) has become a major 
public health problem with increased prev-
alence in both Asia and Western countries. 
The prevalence of HF in Asia is 1.2%–6.7% 
depending on the population studied.1 In 
China, there are 4.2 million HF patients, and 
500 000 new cases are being diagnosed each 
year.1 Although the survival rate after HF 
diagnosis has been increased due to improve-
ment in medical therapy, the mortality of HF 
strengths and limitations of this study
 ► This study is the first multicentre registry study in 
China, aimed to investigate the feasibility and ac-
curacy of applying machine learning (ML) to predict 
sudden cardiac death (SCD) in heart  failure (HF) 
patients with low left ventricular ejection fraction 
(LVEF).
 ► A broad range of outcomes, including SCD, all-cause 
death, lethal arrhythmia, sudden cardiac arrest, car-
diopulmonary resuscitation and rehospitalisation 
due to HF, will be evaluated in this study, and the 
corresponding prognostic models will be developed.
 ► ML and the traditional multivariable Cox proportional 
hazards regression model will be derived from the 
same database and be compared.
 ► HF patients with LVEF  >35% will not be included 
based on the design of this study, which will restrict 
the application of the results of this study to the HF 
with low LVEF.
 ► It might be difficult to determine the endpoint of this 
study sometimes for some patients, when dealing 
with SCD, lethal arrhythmia and sudden cardiac ar-
rest, especially when outside the hospital.
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remains high. Around 50% of people diagnosed with HF 
will die within 5 years.2 The two most common causes 
of death in patients with HF are sudden cardiac death 
(SCD) and progressive pump failure. SCD in HF patients 
is usually caused by lethal arrhythmias such as ventricular 
tachycardia or ventricular fibrillation, and is reported to 
be responsible for ~50% of all cardiovascular death in HF 
patients.3 4 
The most effective strategy for prevention of SCD in 
patients with HF is the implantable cardioverter-defibril-
lator (ICD), associated with 54% relative risk reduction in 
primary prevention,5 and 50% relative risk reduction in 
arrhythmia-related death in secondary prevention.6 There 
is a higher risk of SCD in patients with left ventricular 
ejection fraction (LVEF) ≤35% than with LVEF >35%.7 
At present, LVEF ≤35% is the major ICD indication for 
primary prevention of SCD.8 However, real-world data 
show that only 3%–5% of ICD patients for primary preven-
tion with LVEF ≤35% receive shock therapies on an annual 
basis,9 whereas some SCD victims have LVEF >35%.10 11 
Identifying the patients who will be most likely to benefit 
from primary prevention ICD is urgently needed. Based 
on the latest literature, LVEF ≤35% is still an indepen-
dent predictor of all-cause and cardiovascular mortality 
in chronic systolic HF, and displays a better combination 
of sensitivity and specificity than 40% cut-off.12 Finding 
ways to evaluate the SCD risk in patients with lower EF 
will be more efficient and economically significant. 
Furthermore, a noticeable decline in the rate of SCD for 
HF patients with reduced LVEF has been observed, which 
was consistent with the cumulative benefit of optimising 
medication including ACE inhibitor (ACEI) or angio-
tensin receptor blocker (ARB), beta-blocker and miner-
alocorticoid receptor antagonist (MRA).13 Therefore, it is 
imperative to update the criterion for ICD implantation.
Over the last decade, lots of multivariate prognostic 
models derived for chronic HF patients have been 
proposed (table 1).14–25 However, these models are not 
appropriate to identify ICD candidates at high risk of 
SCD in HF patients with low LVEF. Most above prognostic 
scores were developed form trial databases, and the 
subjects included various types of HF. There is no specific 
study for the prognosis of low LVEF population. Addi-
tionally, although all the scores are ‘not parsimonious’, 
some critical factors are not incorporated into the prog-
nostic models, for example, medications are contained in 
Irbesartan in Heart Failure With Preserved Ejection Frac-
tion Study (I-PRESERVE),17 Meta-Analysis Global Group 
in Chronic Heart Failure (MAGGIC)21 and Cardiac and 
Comorbid Conditions HF (3C-HF).23 Optimised medica-
tion was not required as inclusion criteria in all 12 studies. 
Furthermore, the most above prognostic models are not 
able to predict SCD risk. In recent years, the advances 
in strain echocardiography,26 27 cardiac magnetic reso-
nance26 27 and cardiac radionuclide imaging28 29 have 
provided essential insights into the mechanisms of 
Table 1 The risk model for HF in the literature
Author Database Year Variables (n) Patients (n) Endpoints
Agostoni14 MECKI 2012 6 2716 Cardiovascular death; urgent cardiac 
transplant
Barlera15 GISSI-HF 2013 14 6975 All-cause mortality
Collier16 EMPHASIS-HF 2013 10 2737 All-cause mortality
Komajda17 I-PRESERVE 2011 12 4128 All-cause mortality
Levy18 SHFM 2006 14 1125 Survival
O'Connor19 HF-ACTION 2012 4 2331 All-cause mortality
Pocock20 CHARM 2006 21 7599 All-cause mortality
Pocock21 MAGGIC 2012 13 39 372 All-cause mortality
Senni22 CVM-HF 2006 13 292 All-cause mortality
Senni23 3C-HF 2013 11 2016 All-cause mortality; urgent heart 
transplant (1 year)
Vazquez24 MUSIC 2009 10 992 All-cause mortality; cardiac mortality; 
pump failure death, sudden death
Uszko-Lencer25 BARDICHE-index 2017 8 1811 All-cause mortality; all-cause 
hospitalisation; CHF-related 
hospitalisation
BARDICHE, Body mass index (B), Age (A), Resting systolic blood pressure (R), Dyspnea (D), N-terminal pro brain natriuretic peptide (NT-
proBNP) (I), Cockroft-Gault equation to estimate glomerular filtration rate (C), resting Heart rate (H), and Exercise performance using 6-min 
walk test (E); CHARM, the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidityj; CVM-HF, CardioVascular 
Medicine Heart Failure index; EMPHASIS-HF, the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure trial; GISSI-
HF, Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart failure Trial; HF, heart failure; HF-ACTION, A Controlled 
Trial Investigating Outcomes of Exercise TraiNing trial; MECKI, Metabolic exercise test data combined with cardiac and kidney indexes; 
MUSIC, MUerte Subita en Insuficiencia Cardiaca study; SHFM, the Seattle Heart Failure Model. 
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ventricular arrhythmias, and have been recommended to 
predict the SCD in patients with HF. Although these new 
methods are effective and non-invasive, the widespread 
use in large HF population to predict SCD is difficult, due 
to high equipment and technical requirements. Resting 
12-lead ECG and Holter, as the longest surviving, broadly 
available, quickly deployed and inexpensive tests, can 
provide a measure of cumulative electrical risk, which 
may be combined with other factors to improve the SCD 
risk prediction.30
Based on above reasons, the novel risk assessment 
tools should meet the following requirements: (1) the 
risk model should be developed from the population 
with low LVEF (≤35%) to accelerate its clinical applica-
tion and promote the accuracy of ICD indications for 
primary prevention. (2) More cardiac and non-cardiac 
factors beyond LVEF should be included. (3) Electrical 
risk factors should be included as candidate predictors 
to evaluate the risk of sudden arrhythmic death. (4) 
Although sometimes it is not easy to determine the cause 
of death, SCD as the primary endpoint should be defined 
whenever possible.
Data processing is the crucial step to develop the prog-
nostic models. This study involves non-linear prediction 
models, a large number of patients and numerous predic-
tors with complicated correlations. Traditional hypothe-
sis-driven statistical analysis is difficult to overcome these 
challenges. The machine learning (ML) approaches have 
great potential to improve the solution. They employ 
computer algorithms to identify patterns in large datasets 
with a large number of variables, analyse rules automati-
cally and build both linear and non-linear models in order 
to make data-driven predictions or decisions.31 Weng et 
al32 found that ML significantly improved the accuracy 
of cardiovascular risk prediction, increased the number 
of patients who could benefit from preventive treatment 
and avoided unnecessary treatment. Recent studies have 
shown that the application of ML techniques may have 
the potential to improve HF outcomes and management, 
including cost savings by improving existing diagnostic 
and treatment support systems.33 ML algorithms also have 
been applied to predict SCD in some recent studies and 
results indicate their significant advantages for predicting 
SCD.34 35 However, more studies based on large-scale 
cohort are needed to evaluate ML for prediction of SCD 
in HF patients. Therefore, the application of ML for the 
prediction of SCD in HF patients with low LVEF is techni-
cally innovative and clinically significant.
AIMs
The purpose of our study is to develop and validate 
new models to improve the prediction of SCD in HF 
patients with low LVEF. The new strategies of identifying 
HF patients most likely to benefit from primary preven-
tion ICD will improve the revolution of ICD indications. 
The specific research objective is to develop prediction 
models to evaluate prognosis and SCD risk, respectively, 
by ML methods and traditional Cox proportional hazard 
regression in HF patients with low LVEF (≤35%).
MEthods And AnAlysIs
study design
This study is a retroprospective, multicentre, non-inter-
ventional, observational clinical registry. The primary 
sponsor is The First Affiliated Hospital of Nanjing 
Medical University. The study will be conducted 
across 14 cardiovascular departments in tertiary A 
hospitals throughout the People's Republic of China 
(see online supplementary file 1).
The cases from January 2016 to December 2017 in the 
First Affiliated Hospital of Nanjing Medical University 
and Xiamen Cardiovascular Hospital Xiamen Univer-
sity will be collected retrospectively and followed-up 
prospectively. About 500 retrospective cases meet the 
inclusion criteria according to preliminary estimation. 
The prospective recruitment has started in the above 
14 hospitals since January 2018. The retrospective 
cases and the first 1000 prospective cases will be used 
to develop the prediction models. And the next 1000 
prospective cases will be used for model validation. The 
flow diagram of the progress is illustrated in figure 1.
Inclusion criteria
To participate in this study, patients must comply with all 
of the following.
1. Diagnosis of heart failure with reduced EF (HFrEF) 
according to the 2016 European Society of Cardiology 
(ESC) HF guideline.8
2. LVEF ≤35% (measured by Simpson’s methods) after 
optimised medication including ACEI or ARB, be-
ta-blocker and MRA if available and not contraindicat-
ed at least 3 months.
3. Signed informed consent.
Exclusion criteria
The patient with any of the following will be excluded.
1. Hypertrophic cardiomyopathy.
2. Rheumatic heart disease.
Figure 1 Flow diagram of progress. HF, heart failure; LVEF, 
left ventricular ejection fraction. 
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3. Congenital heart disease.
4. Pulmonary heart disease.
5. Pericardial diseases and myocarditis.
6. Acute myocardial infarction in recent 3 months, in-
cluding ST segment elevated myocardio infarction 
(STEMI) and NSTEMI.
7. Aortic dissection.





12. Application of other interventional clinical trials.
13. Non-drug therapies for improving heart function: 
cardiac resynchronization therapy with or without im-
plantable cardioverter-defibrillator (CRT-P/D), ICD, 
heart transplantation, surgical resection of ventric-
ular aneurysm, interventional left ventricular resto-
ration with Revivent/Parachute system), MitraClip 
therapy for recurrent mitral regurgitation.
Endpoints
Primary endpoint
All-cause death and SCD, including cardiac death and 
death from other causes.
Secondary endpoint
Lethal arrhythmia, sudden cardiac arrest, cardiopulmo-
nary resuscitation, rehospitalisation due to HF.
recruitment and consent
Participants will be identified and recruited at each of 
the participating centres. The clinical status of potential 
participants will be assessed, and their medical records 
will also be reviewed to confirm the eligibility according 
to the inclusion and exclusion criteria.
The study details will be explained to all potentially 
eligible and interesting subjects. The patients who agree 
to attend this study will sign the informed consent form 
(ICF) indicating that they fully understand the study 
and their rights of confidentiality and withdrawal from 
the study without giving a reason.
baseline evaluation
Prognostic models of HF in the last 10 years have 
been reviewed, and the associated risk factors have 
been ranked according to their corresponding HR 
in respective risk models (table 1, figure 2). Age, sex, 
New York Heart Association (NYHA) class, LVEF, prior 
HF hospitalisation, course of HF, severe valvular heart 
disease, atrial fibrillation, prior myocardial infarction/
coronary artery bypass grafting (CABG), renal dysfunc-
tion, chronic obstructive pulmonary disease (COPD), 
diabetes mellitus (DM), ischaemic aetiology, decreased 
systolic pressure, low body mass index, anaemia, hypo-
natremia, high N-terminal probrain natriuretic peptide 
(NT-proBNP), uricemia and current smoker were 
included. Variables which were not listed in previous 
models but appear relevant to higher risk of SCD in 
HF patients, and would therefore, merit consideration, 
including syncope or presyncope, frequent premature 
ventricular beat, non-sustained ventricular tachycardia, 
complete left bundle branch block, long QT interval 
and increased QT dispersion. In addition, self-care 
ability, social support and psychological state including 
depression and anxiety, are also predictors for subse-
quent poor prognosis in HF patients. The above risk 
factors have been assessed and confirmed by an expert 
panel of cardiologists and statisticians and will be 
collected in this study particularly.
Figure 2 HR of variables in different risk models. Af, atrial fibrillation; BMI, body mass index; BNP, brain natriuretic 
peptide; CABGB, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HR, 
heart rate; ICM, ischaemic cardiomyopathy; MI, myocardial infarction; NYHA, New York Heart Association; SBP, systolic blood 
pressure; VHD, valvular heart disease.
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The baseline data that will be collected in all eligible 
subjects are as follows.
 ► Demographic characteristics: date of birth, gender, 
height and weight.
 ► Lifestyle behaviour: smoking and drinking status.
 ► Vital signs: blood pressure and heart rate.
 ► NYHA class.
 ► Aetiology of HF: the ischaemic aetiology will be 
confirmed if any following point is met: (a) prior 
myocardial infarction or revascularisation history 
(CABG/percutaneous coronary intervention); (b) 
left main or proximal segment of the left anterior 
descending artery stenosis ≥75% showed by coronary 
angiogram (CAG); (c) at least two main coronary 
artery branches stenosis ≥75% showed by CAG. Other-
wise, non-ischaemic HF should be identified.
 ► Prior HF hospitalisation history: first HF hospitali-
sation or not, times of prior HF hospitalisation, the 
course of HF (since the HF symptoms appear; if 
unavailable, since the decreased EF was found).
 ► Coronary heart disease history: myocardial infarc-
tion or angina history, CAG result, revascularisation 
history, recent angina.
 ► Arrhythmia history: atrial fibrillation, atrial flutter, 
premature atrial contraction (PAC), premature 
ventricular contraction (PVC), non-sustained VT 
(NSVT), sustained VT, ventricular fibrillation and 
some bradyarrhythmias.
 ► Syncope or presyncope history.
 ► Cardiac arrest/cardiopulmonary resuscitation history.
 ► Other histories: hypertension, DM, COPD.
 ► Echocardiography: LV end-diastolic volume, LV 
end-systolic volume and LVEF measured by Simpson’s 
method; left atrial diameter, LV end-diastolic diam-
eter and LV end-systolic diameter, pulmonary artery 
systolic pressure. The status of valve regurgitation will 
be evaluated (0-none; 1-mild; 2-mild to moderate; 
3-moderate; 4-severe).
 ► ECG: left/right bundle branch block will be recorded. 
QRS duration and QT interval will be tested, and QT 
dispersion will be calculated.
 ► Holter: total heartbeat of the whole day, minimum/
maximum/ average HR, onset of PVC, PAC, NSVT, 
VT, atrial fibrillation/flutter.
 ► Laboratory tests results: serum creatinine, blood urea 
nitrogen, serum natrium, haemoglobin, thyroid-stim-
ulating hormone, free triiodothyronine, free 
thyroxine, NT-proBNP.
 ► Medication: ACEI/ARB, beta-blocker, aldosterone 
antagonist, diuretic, digoxin, antiplatelet agent, 
anticoagulant, statin, calcium channel blocker, anti-
arrhythmics, Ivabradine and angiotensin receptor 
blocker-neprilysin inhibitor.
 ► Evaluation of self-care behaviour and social support: 
9-item European Heart Failure Self-care Behaviour 
Scale (9-EHFScBS)36 will be used to determine the 
self-care levels in HF patients. Social Support Rating 
Scale (SSRS)37 will be used to evaluate the social 
support condition in HF patients.
 ► Assessment of psychological status: Hamilton Depres-
sion Scale (HAMD) and Hamilton Anxiety Scale 
(HAMA).
Table 2 The checklist for data collection
Data collection
Baseline
Regular visit Withdraw/deathRetrospective cases Prospective cases















Survival state √ √ √
Adverse event Once happen √
Study bias Once happen √
Withdraw from the study Once happen √
Death Once happen √
9-EHFScBS, 9-item European Heart Failure Self-care Behaviour Scale; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; 
SSRS, Social Support Rating Scale. 
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 ► Socioeconomic and educational status: marital status, 
educational status, monthly income, sources of 
medical expenses, medical insurance.
Patient visits
After being enrolled in this research, all the subjects will 
be followed-up periodically in the outpatient department 
or by telephone interview every 3 months. The compli-
ance with medications will be evaluated. As the primary 
endpoint, all-cause death and SCD will be focused. Cause 
of death will be analysed in detail. SCD is defined by the 
WHO as unexpected death that occurs within 1 hour 
from the onset of new or worsening symptoms (witnessed 
arrest) or, if unwitnessed, within 24 hours from when 
the individual was last observed alive and asymptom-
atic.38 The lethal arrhythmia including ventricular tachy-
cardia/ ventricular fibrillation (VT/VF), sudden cardiac 
arrest, cardiopulmonary resuscitation and rehospitalisa-
tion due to HF will be recorded carefully.
Figure 3 Study framework and process. HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart 
Association; SCD, sudden cardiac death.
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During follow-up, lethal arrhythmia will be recognised 
more precisely for patients who receive ICD or cardiac 
resynchronization therapy with implantable cardio-
verter-defibrillator (CRT/D) implantation, and will 
be recorded as an adverse event (AE). The patients, 
who receive CRT-P/D, heart transplantation, surgical 
resection of a ventricular aneurysm, interventional left 
ventricular restoration with Revivent/Parachute system, 
MitraClip therapy for recurrent mitral regurgitation, or 
some other non-drug therapy to improve heart function, 
will be followed up as usual.
data collection
In the prospective part, clinical data of subjects will be 
collected and filled in the electrical data capture (EDC) 
system at baseline and particular follow-up visit. In the 
retrospective part, the same baseline information, except 
for 9-EHFScBS, SSRS, HAMD and HAMA questionnaires, 
will also be captured and input into the EDC system. 
The following prospective visits (every 3 months) will be 
conducted regularly and will be recorded in the EDC 
system. Investigators will record all the information of 
AEs, study bias, withdrawal from the study or death in 
EDC system. In this study, the participants will be iden-
tified by study codes, and their names will not appear in 
the EDC system. All the personal information including 
contact information, medical record and outcome will not 
be revealed to any person who has not been authorised by 
a principal investigator. Professional staffs are responsible 
for database management, data maintenance and regular 
data backup. Data quality will be monitored regularly. 
The data collection checklist is showed in table 2.
data preprocessing
All above-collected variables, which might be predictors 
of all adverse prognosis of HF described in endpoint 
events, will be classified as uncontrollable variables (eg, 
age, gender, history), controllable variables associated 
with heart (eg, NYHA class, LVEF, increased heart rate) 
and controllable variables beyond heart (eg, smoking, 
anaemia, DM). Appropriate dummy variables will be 
used for binary variables and categorical variables, and 
quantitative variables will be fitted as a single continuous 
measurement (eg, age, heart rate, NT-proBNP), unless 
there is clear evidence of non-linearity. In order to create 
a practice simple risk score, some continuous variables 
will also be categorised into several groups according to 
both common clinical cut points and expert advice.
Machine learning
Variable selection is the process of selecting a subset of 
relevant variables for use in model construction, which 
can substantially reduce the abundant information and 
decrease the number of variables that are input to the 
prediction model. In this study, the technique named as 
‘information gain ranking’ will be used to select appro-
priate variables. Information gain represents the effective-
ness of a variable based on entropy, which characterises 
the unpredictability of a system. The information gain of 
a variable is evaluated as the entropy difference of the 
system when including and excluding this variable. Then, 
the variables whose information gain scores are less than 
a threshold are considered to be insignificant and will be 
excluded from the prediction.
Prediction models for SCD in HF patients will be devel-
oped by the following classification algorithms, respec-
tively: decision trees, logistic regression, support vector 
machine, random forest and artificial neural network.29 
The performance and general error estimation of these 
ML models will be assessed by 10-fold cross-validation. 
The dataset will be randomly divided into 10 equal 
folds. Ninefolds will be used as the training set with the 
remaining onefold as the validation set. The validation 
results from 10 repeats will be combined to provide a 
measure of the overall performance. The prediction 
models derived from the above classification algorithms 
above will be evaluated based on the accuracy, sensitiv-
ities, specificities and the area under the receiver-oper-
ating characteristic (ROC) curve. Finally, clinical experts 
and computer specialists will discuss and choose the best 
model to predict the prognosis of SCD in HF patients 
and then perform further validation with the prospective 
dataset.
Cox proportional hazards regression
Univariable Cox proportional hazards modelling will be 
used to identify strong independent baseline candidate 
predictors for the primary and secondary outcomes. We 
will use both forward and backward stepwise procedure to 
derive the multivariable Cox proportional hazards model 
with p<0.05 as the inclusion criterion. Every variable in 
the model will be multiplied by its β-coefficient, and the 
products will be summed to calculate the risk score. Risk 
function will be used to estimate the level of risk. The 
calculating formula is as follows.39
P=h (t j; X k)=h0 (t j) exp (SCORE)
SCORE=Xk ßk = ß0 +ß1×1 +ß2×2 +………ßp xp
Model validation
The dynamic prospective cases will be used for external 
validation of the optimal ML and Coxproportional 
hazards models. The validation will be performed using 
the models to calculate the probability of the outcome of 
interest occurring for each individual included in the vali-
dation sample when compared with the events actually 
observed to occur in this sample. The discrimination of 
each model will be estimated by ROC curve. The calibra-
tion of the models will be assessed by the Hosmer-Leme-
show goodness-of-fit test. The ML prediction model will 
be compared with the Cox proportional hazards regres-
sion model.
Patient and public involvement
During the design of this study, a survey of patient 
requirements, including communication needs, follow-up 
frequency and visit cost, was conducted in population 
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of potential HF participants, which provided important 
evidence for drawing up this study protocol to meet most 
of the patients’ needs, build close contact with patients, 
enhance the overall adherence and improve the accuracy 
of endpoint event. This study is not a patient-led research, 
and patients are not involved in the recruitment of the 
study. The study results will be informed to the partici-
pants by phone at the end of this study. The alive patients 
will be evaluated with the new prediction model, and the 
ICD intervention will be recommended to the high SCD 
risk patients.
study timeframe
The retrospective data collection in the two subcen-
tres started in March 2017, and prospective enrolment 
in all 14 subcentres has started in January 2018. The 
follow-up period is scheduled to end in December 2019. 
The major part of data analysis will be performed from 
January to June 2020. The study framework and process is 
summarised in figure 3.
EthICs And dIssEMInAtIon
All necessary information about this study will be disclosed 
to the patients. Every subject will be asked to sign the ICF, 
indicating that they fully understand the study and volun-
tarily participate in this study. All results of this study will 
be published in international peer-reviewed journals and 
presented at relevant conferences.
dIsCussIon
The evaluation of SCD risk in HF patients is a problem 
that urgently needed to be solved. The existing predic-
tion strategies for the SCD risk in HF patients lack clin-
ical practice value for various reasons. ICD indication 
for primary prevention of SCD could be optimised by 
identifying the high SCD risk patients in HF with low 
LVEF (≤35%). It is of great practical value and economic 
significance.
We reviewed some predictive studies of HF in the past 
years and ranked the risk factors according to their corre-
sponding HR, which have been included in our study as 
candidate risk factors. Otherwise, some other variables 
which appear relevant to risk of SCD in HF patients are 
also collected. Therefore, the efficiency and practicality of 
predictive model development has been highly improved.
This study is the first multicentre registry study in 
China, aimed to investigate the feasibility and accuracy of 
applying ML to predict SCD in HF patients with low LVEF. 
A broad range of outcomes, including SCD, all-cause 
death, lethal arrhythmia, sudden cardiac arrest, cardio-
pulmonary resuscitation and rehospitalisation due to HF, 
will be evaluated in this study, and the corresponding 
prognostic models will be developed. ML and the tradi-
tional multivariable Cox proportional hazards regression 
model will be derived from the same database and will be 
compared.
The limitations of this study are as follows: (1) HF 
patients with LVEF >35% will not be included based on 
the design of this study, which will restrict the application 
of the results of this study to the HF with low LVEF. (2) It 
might be difficult to determine the endpoint of this study 
sometimes for some patients, when dealing with SCD, 
lethal arrhythmia and sudden cardiac arrest, especially 
when outside the hospital.
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